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ABSTRACT
The CDC states that there has been a dramatic increase in obesity from 1990 to
2010. Type-II diabetes and obesity prevalence are increasing worldwide.

Often,

obesity and Type-II diabetes are concurrent, and predispose individuals to
development of fatty liver disease, referred to as Non-alcoholic fatty liver disease
(NAFLD). Perfluorooctane sulfonic acid (PFOS) and perfluorooctanoic acid (PFOA)
are two commonly studied perfluorinated compounds (PFC’s) that are considered
environmental toxicants that have the potential to elicit diabetic and NAFLD
phenotypes. This dissertation presents novel findings of gaps within the literature to
date. Traditionally, diabetes and obesity have been discussed in regard with genetics,
diet and old age. Now, risk factors that also need to be considered are environmental
chemicals. We found that PFOS elicits an insulin-resistant phenotype in adult mice,
where they were not utilizing glucose as readily compared to the controls. The effect
of PFOS on therapeutic management interventions has not previously been looked at.
Here, we show that PFOS interferes with the Metformin-induced decrease in glucose.
We also found a vast increase in the hepatic triglycerides with PFOS exposure. In this
thesis, PFOS was administered in a sub-chronic low dose (100μg/kg) daily to mice fed
ad libitum or placed on caloric restriction (CR) for five weeks. In the cohort we
generated, we observed that PFOS exposure increased hepatic lipid content in mature
male mice fed ad libitum and dampened the observed CR-induced decrease in hepatic
lipids. PFOS administration did not affect glucose tolerance in ad libitum fed mice,
but did interfere with CR-induced improvement of glucose tolerance. This was further
associated with suppression of IRS-1 mRNA expression in liver. As hepatic lipid

content is closely tied to insulin and glucagon signaling for hepatic glucose
production, it was determined whether the observed effects in vivo were due to PFOSstimulated hepatic glucose production. Using cultured mouse hepatocytes under low
glucose conditions, it was evaluated whether PFOS could enhance glucagonstimulated glucose production. PFOS stimulated hepatocyte glucose production and
also enhanced glucagon-induced glucose production. Furthermore, in HEPG2 cells,
PFOS exposure (25 and 250 µM) significantly increased glucose output and AiCar,
which suppresses glucose production, was ineffective in the presence of PFOS. These
findings provide a mechanistic explanation for the decreased glucose tolerance in our
in vivo mouse cohort. PFOS increases glucose output from the in vitro models, even
when challenged with metformin or AiCar, as well as, decreases the glucose
utilization in the in vivo mouse study suggesting that it has a glucagon-like effect.
PFOA is a perfluorinated carboxylic acid also commonly found in the
environment. According to the EPA, low levels of PFOA are widely distributed in
environmental media (Houde et al., 2011; Gewertz et al., 2013) and in the blood of the
general United States population. The EPA states that PFOA is a known liver toxicant,
development toxicant, and carcinogen in rodents. It has been detected in human liver,
kidney and adipose tissue ranging from 0.3 to 3.8ng/g with the highest concentrations
within the liver (Maestri et al., 2006). In another study, PFOA is considered an
obesogen to mid-aged mice where insulin and leptin levels were altered at a very low
concentration (Hines et al., 2009). PFOA is a Potent activator of peroxisomeproliferator activated receptor-alpha (Ppar-α) contributing to oxidative stress and
activation of fatty acid oxidation pathways in hepatocytes. Given its persistence, the

purpose of this study was to evaluate whether PFOA treatment affects fatty acid
oxidation, lipid synthesis, and antioxidant response gene expression in adipose tissue
in adult male mice. Utilizing an exposure paradigm characterized by the
Environmental Protection Agency, adult male mice were treated with 1.0 or 3.0 mg
PFOA ammonium salt/kg for 7 days. Adipose tissue was collected and total RNA was
isolated. Analysis of mRNA was completed by quantitative PCR. For the most part,
gene expression in adipose tissue from vehicle- and PFOA-treated mice was similar.
Literature lacks data on PFOA in adipose tissue and in human health, which continue
to be discovered. Given its persistence, longer exposure periods and protein expression
changes

should

be

examined.
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PREFACE
The following thesis project is in Manuscript Format. Based on our previous lab
findings, the initial goals of this thesis project were to evaluate different models for
changes and regulation of Nrf2, a transcription factor. However, after interesting
observations with perfluorinated compounds (PFC’s), my thesis evolved into a more
focused and mechanistic study on Perfluorooctanesulfonic acid (PFOS), a major PFC.
The bulk of the thesis work has been to understand whether PFOS exposure can
interfere with the benefits of caloric restriction in vivo or in vitro. Epidemiology
studies associating PFOS exposure with altered metabolics has further provided
justification for studying PFOS effects.
Because the thesis is manuscript format, there have been experiments not
included in the manuscript, but still essential to key observations of the thesis work.
These have been included. Appendix material will also present findings for PFOS and
PFOA with regard to adipose tissue and gene expression, along with work performed
regarding the Nrf2 activating compounds, oleanolic acid (OA) and butylated
hydroxyanisole (BHA), on interaction with a lithogenic diet that I generated early in
my graduate career.
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Chapter 1
Introduction to liver disease and perfluorinated compounds
Non-alcoholic fatty liver disease (NAFLD) statistics and etiology
NAFLD is a common chronic liver disease that is increasingly growing within the
general population affecting 30% of adults, 20% of children and 69% of type 2
diabetic (T2D) patients in the United States (Ahmed et al., 2015; Leite et al., 2009;
McCullough, 2006). Features of metabolic syndrome are commonly found in NAFLD
such as obesity (67-71%), disturbed lipid profiles (57-68%) and hypertensive (3670%) (Ahmed et al., 2015). NAFLD is defined by evidence of steatosis by imaging or
histology without any secondary hepatic fat accumulation such as alcoholic
consumption (Chalasani et al., 2012). Major risk factors for NAFLD include obesity,
type-2 diabetes (T2D) and dyslipidemia (Chalasani et al., 2012). More than 90% of
NAFLD patients have insulin resistance or feature metabolic syndrome (Ahmed et al.,
2015). Non-alcoholic steatohepatitis (NASH) is the most severe histological form of
progress to cirrhosis with 20-30% of these patients experiencing a liver-related death
(McCullough, 2006).
Mechanisms contributing to
NAFLD
NAFLD
insufficient

can

result

from

adiponectin

release

from adipose tissue (Polyzos et al.,
2009). Adiponectin levels decrease
Figure C1-1. Schematic depicting the overall outcome
of decreased circulating adiponectin levels.

1

as fat mass increases, thereby

resulting in subsequent signal transduction consequences within cells (Polyzos et al.,
2009). One of these consequences is insulin resistance (IR) (Polyzos et al., 2009).
With IR, glucose uptake is decreased and fatty acid oxidation are decreased while
gluconeogenesis, de novo synthesis lipogenesis are increased creating a cycle of
obesity, IR and the subsequent fatty liver (Polyzos et al., 2009) (Figure C1-1). A
dysregulation and an imbalance of adipokines/cytokines are abundantly found in
NAFLD and have been shown to lead to IR and fatty liver (Watanabe et al., 2008;
Takei et al., 2006; Jarrar et al., 2008). Adiponectin is an adipose-specific adipokine
that acts on amp-activated protein kinase (AMPK) within the liver protecting from
insulin resistance (IR) and ultimately, fatty liver (Polyzos et al., 2009) (Figure C1-2).
Upon activation, AMPK down-regulates sterol regulatory element-binding proteins
(Srebp), which are a group of membrane-bound transcription factors that regulate lipid
synthesis (Kohjima et
al., 2008). Specifically,
Srebp1c regulates the
expression
encoding

of

genes

lipogenic

enzymes such as acetylCoA carboxylase (Acc1)
and fatty acid synthase
Figure C1-2: Schematic depicting
contributing to NAFLD.

molecular

(Fas)

(Kohjima et al.,

2008).

In NAFLD, as

mechanisms

adiponectin is decreased,

2

AMPK activation is also decreased resulting in Srebp1c activation and lipid synthesis
via Acc1 and Fas within the liver eliciting a fatty liver (Kohjima et al., 2008) (Figure
C1-2).
Therapeutic strategies for NAFLD Treatment
The recommended therapeutic intervention to treat NAFLD is with diet and exercise,
which have the ability to reverse hepatic lipid accumulation (Chalasani et al., 2012).
It has been shown that a calorically restricted (CR) diet with exercise decreases the
hepatic steatosis and serum lipids in overweight patients with NAFLD (Larson-Meyer
et al., 2008).

In earlier studies, it is suggested that CR with or without exercise

decreases liver fat and liver enzymes with no difference between CR groups with the
CR and exercise groups (Yoshimura et al. 2014; Straznicky et al., 2012; Tamura et al.,
2005; Larson-Meyer et al., 2008). In a randomized-controlled study trial of NAFLD
patients, intervention with diet, after 12-months, 64% patients were in NAFLD
remission which includes a reduction in body weight and total cholesterol levels
(Wong et al., 2013). NAFLD can be reversed with CR intervention.
Molecular Mechanisms by which CR decreases Liver Fat
The response to CR hinges upon a cellular metabolic shift in which AMPK is a central
mediator. CR induces phosphorylation of AMP-activated protein kinase (AMPK)
upon redox status (high AMP:ATP ratio) (Figure C1-3).

AMPK is a regulator of

hepatic metabolism in energy balance by promoting catabolic pathways and inhibiting
ATP-consuming pathways and is a good target for the treatment of T2D (Viollet et al.,
2006). AMPK activation is implicated for the benefits of glucose and lipid metabolism
with exercise, weight loss, and use of anti-diabetes drugs (Towler et al., 2007).

3

AMPK inhibits hepatic glucose and lipid synthesis and induces lipid oxidation to
produce energy (Nerstedt, 2010).

Figure C1-3: Schematic depicting molecular mechanisms in caloric restriction
and excess.

In addition to caloric restriction, metformin has been examined as a pharmacologic
therapeutic intervention for the management of NAFLD (Mazza et al., 2012).
Metformin was first introduced in the 1950’s as a first-line T2D drug due to its ability
to lower gluconeogenesis and ultimately blood glucose levels which increase glucose
uptake within skeletal muscle as well as fatty acid oxidation within adipose tissue
(Stumvoll et al. 1995) (Figure C1-4).
Metformin is used in the treatment of T2D and activates AMPK in hepatocytes, which
in turn suppresses lipogenic genes, such as SREBP1c and Acetyl-CoA carboxylase
(ACC) while increasing insulin sensitivity (Viollet et al. 2012; Zhou et al., 2001).
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Introduction to
Perfluorinated
Compounds:
Perfluorinated
compounds (PFCs) are a
group

of

synthetic

anthropogenic
organofluorines
Figure C1-4. Schematic of the pathogenesis of metformin within
liver and peripheral tissues.

used
industrial

in

widely
various

applications

such as stain-resistant coatings for paper and fabric protection, leather, waxes,
surfactants, emulsifiers, fire-fighting foams, textiles, chromium plating and more
(Wan et al. 2012, Ziwen et al., 2014). The main routes of human exposure are
through ingestion, dermal exposure, inhalation and through drinking water (Saikat et
al., 2012). The main route of general population exposure to PFOS is via ingestion of
fish and drinking water (Saikat et al., 2012). There has been no evidence reported of
the transformation of PFOS in soil, sediment or water (Saikat et al. 2012).
Perfluorinated chemicals have been studied for a couple of decades and are known to
induce fatty liver in rodents (EPA, 2009a; Hines, et al. 2009; Klaunig, et al. 2003;
Tardiff, et al. 2009). Perfluorooctanesulfonic acid (PFOS) is a major 8-carbon PFC
that is widely studied today. PFOS has been detected in the sera and tissues of
animals, specifically fish, birds, and marine mammals, and humans worldwide (Giesy
and Kannan, 2001; Calafat et al., 2007; Lau et al., 2007) and have been correlated

5

with adverse health effects in rodents and monkeys, including liver effects and
decreased cholesterol (Lau et al., 2007, Seacat et al., 2002). PFOS has also been
associated with energy metabolism disorders due to Ppar activation in rats (Bjork et
al., 2008). Environmental exposure of PFOA and PFOS to adult humans were
associated with increased lipid levels (Eriksen et al., 2013; Chateau-Degat et al.,
2010), however, in mice and monkeys, there is a negative correlation with cholesterol
levels (Seacat et al., 2003; Seacat et al., 2002). Moreover, in adolescents and adults,
increased serum PFOS concentration was associated with increased blood insulin,
assessment of insulin resistance, and beta-cell function (Lin et al., 2009). Altered
glucose and lipid metabolism has also been described in adult rats exposed to PFOS
(Lv et al., 2013).
Perfluorooctanoic acid (PFOA) is another PFC, but instead of the sulfonate
moiety, it has a carboxylic acid. According to the EPA, PFOA has been investigated
since the 1990s and is now a known liver toxicant (hepatomegaly), development
toxicant, and carcinogen in rodents. It is detected in serum and tissues of wildlife and
humans worldwide with an average half-life of 3.5 years in humans (EPA, 2009a;
Hines, et al. 2009; Klaunig, et al. 2003; Tardiff, et al. 2009). Human studies of PFOA
are limited, however, trace amounts of PFOA have been detected in adipose tissue
(0.2ng/kg) (Calafat, et al., 2007). It is known that PFOA accumulates mostly in liver
and kidney and is detectable in serum (Hundley et al., 2006; Olsen et al., 2005).
PFOA exposure has resulted in weight loss with liver injury and lipid metabolism
disorders in mice (Seacat et al., 2002; Jensen et al., 2008).
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Levels of PFOA and PFOS were detected in non-occupationally exposed
general population humans of liver, kidney, adipose tissue, brain, basal ganglia,
hypophysis, thyroid, gonads, pancreas, lung, skeletal muscle and blood and found
PFOA ranging from 0.3 to 3.8ng/g and PFOS ranging from 1.0 to 13.6ng/g with the
highest concentrations within the liver (Maestri et al., 2006). Low doses of PFOA and
PFOS have still been suggested to increase hepatomegaly (Wan et al., 2012; Yan et
al., 2014), which may be due to the induction of peroxisome proliferation through the
agonistic nature of PFOA and PFOS on Ppar’s (Pyper et al., 2010; Lau et al., 2007;
Takacs and Abbott, 2007). However, studies with PFOA administration in Ppar-α-null
mice still observed increased liver weight and changes in gene expression associated
with fatty acid metabolism and fat accumulation suggesting Ppar-independent
mechanisms (Minata et al., 2010; Wolf et al., 2008; Rosen et al., 2008a and b).
The purpose of these following dissertation studies was to evaluate PFOS and
PFOA on metabolic tissues of mice treated with these compounds. The overall goal of
Manuscript I was to determine whether PFOS exposure interferes with recommended
therapies to decrease hepatic lipid content that are used to treat NAFLD. It was
hypothesized that PFOS administration could interfere with the benefits of CR and
metformin potentially through targeting AMPK phosphorylation. Overall, we present
novel findings illustrating that PFOS administration concurrent with a modest
reduction in caloric intake thwarted CR-induced decline in hepatic lipids in vivo and
improvement in glucose tolerance and interfered with metformin-induced glucose
lowering effects in vitro. The goal of Manuscript II was to determine whether PFOA
treatment affects fatty acid oxidation, lipid synthesis, and antioxidant response gene
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expression in adipose tissue.

Results indicate no significant findings of PFOA

affecting any gene expression within adipose tissue of mice after a 7-day treatment
with 1.0 or 3.0 mg/kg/day.
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ABSTRACT
A combination of caloric restriction (CR), dietary modification, and exercise is
the recommended therapy to reverse obesity and nonalcoholic fatty liver
disease. The ability to mount an effective response to caloric restriction
required to effectively shift hepatic metabolism to fatty acid oxidation depends
upon induction of pathways, such as AMP- activated kinase (AMPK). PFOS, a
fluoro-surfactant previously used as a stain repellent and anti-stick material
increases hepatic lipids in mice following relatively low dose exposures. We
hypothesized that PFOS administration will interfere with CR-induced
reduction of hepatic lipids and improve glucose tolerance. Adult male C57BL/6
mice were fed ad libitum or 25% reduced calorie diet concomitant with either
vehicle (water) or 100 μg PFOS/kg/day for 6 weeks. PFOS did not significantly
alter CR-induced weight loss or WAT mass or liver weight over 6 weeks.
However, PFOS increased hepatic triglyceride accumulation, and hepatic
triglycerides were higher in PFOS-treated mice that subjected to calorie
restriction, which was associated with

decreased phosphorylated AMPK

protein levels in livers of CR mice.

PFOS interfered with CR-induced

improvement of glucose tolerance with decreased IRS-1 mRNA expression in
liver.

PFOS induced glucose production in hepatocytes and HepG2 cells,

which was partially antagonized by the AMPK activating compound, AiCAR.
Moreover, metformin suppression of gluconeogenesis was not as robust in
HepG2 cells with PFOS co-treatment. Overall, PFOS administration had
disruptive effects for hepatic lipids and glucose homeostasis, and interfered
with beneficial glucose lowering effect of metformin.
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INTRODUCTION
Obesity and T2D are concurrent, and predispose individuals to development of
fatty liver disease, referred to as non-alcoholic fatty liver disease (NAFLD) (Li
et al., 2002). NAFLD is a complex multifactorial disease in the U.S. with 10%
of children, 30% of adults, 50% of obese, 76% of diabetics and 100% of
morbidly obese diabetics affected (Eguchi et al., 2013; Naik et al., 2013;
Reddy and Roa, 2006). It is characterized by the accumulation of lipids in the
liver, lipotoxicity and insulin resistance and thus frequently found in people
with central obesity or diabetes (Naik et al., 2013; Smith and Adams, 2011).
NAFLD as a disease is considered to be a spectrum – ranging from simple
steatosis

to

non-alcoholic

steatohepatitis

(NASH).

Steatosis

is

the

accumulation of triglycerides within the hepatic parenchymal cell cytoplasm,
whereas non-alcoholic steatohepatitis (NASH) consists of classical steatosis
accompanied by inflammation (Naik et al., 2013; Reddy and Roa, 2006).
Hepatic lipid accumulation has been shown to lead to decreased insulin
sensitivity, ultimately leading to insulin resistance, commonly observed in
diabetes (Montell et al., 2001). A hallmark characteristic of hepatic steatosis is
the disequilibrium between de novo lipogenesis, free fatty acid uptake,
oxidation, esterification and secretion of lipids from the liver (Naik et al.,
2013). Hepatic lipid accumulation can be attributed to dampened lipid
utilization via altered mitochondrial oxidation and hepatic lipid export as well as
excess adiposity and decreased insulin sensitivity (Smith and Adams, 2011).
Multiple factors are suggested to contribute to NAFLD and environmental
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exposure has been hypothesized as a potential risk factor for predisposition to
NAFLD (Cave et al., 2007).

The American Association for the Study of Liver Disease NAFLD treatment
guidelines recommends dietary modification and/or weight loss as the current
NAFLD therapeutic strategy (Larter et al., 2013).

The recommended

therapeutic intervention to treat NAFLD is with diet and exercise, which have
the ability to reverse hepatic lipid accumulation (Chalasani et al., 2012). It has
been shown that a CR diet with exercise decreases the hepatic steatosis and
serum lipids in overweight patients with NAFLD (Larson-Meyer et al., 2008). A
diet with 30% caloric restriction without malnutrition delays the onset of
multiple diseases such as diabetes, cancer and cardiovascular disease in
Rhesus monkeys (Colman et al. 2009). A calorie restricted (CR) diet in
humans on average for 6 years improved metabolism and insulin levels
(Fontana et al., 2004). In human studies, diet and exercise were effective in
the reduction of NAFLD (Oh et al., 2014; Schwenger and Allard, 2014). In
addition, caloric restriction mimetics have been examined as potential
treatments for NAFLD.

For example, Metformin, a commonly used anti-

diabetes drug with some CR mimetic properties has been investigated as a
potential therapy to treat NAFLD (Maslak et al., 2014), with some positive
results (Maslak et al., 2014).

CR increases the cellular AMP:ATP ratio, which induces AMP-activated
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protein kinase (AMPK) activation (Fulco and Sartorelli, 2008). AMPK is a
heterotrimeric
homeostasis

serine/threonine
in

metabolic

protein

tissues

kinase

upon

high

that

regulates

AMP:ATP

energy

ratios

with

phosphorylation at the Thr 172 residue of the alpha subunit (Nerstedt, 2010).
AMPK activation is implicated for the benefits of glucose and lipid metabolism
with exercise, weight loss, and use of anti-diabetes drugs (Towler et al., 2007).
AMPK inhibits hepatic glucose and lipid synthesis and induces lipid oxidation
to produce energy (Nerstedt, 2010). AMPK phosphorylates sterol regulatory
element binding protein-1c (SREBP-1c) at Ser-327 inhibiting its activity,
diminishing SREBP1c-mediated lipogenesis reducing hepatic steatosis (Li et
al., 2013). CR increases phosphorylation of AMPK, which then activates Sirt1
deacetylase under certain redox status (Fulco and Sartorelli, 2008).

In

steatotic livers, there is a decrease in AMPK phosphorylation in rodents (Ha et
al., 2011).

Under CR, four overweight males displayed increased

phosphorylated AMPK and SIRT1 in peripheral blood mononuclear cells
(Kitada et al., 2013). AMPK is a regulator of hepatic metabolism in energy
balance by promoting catabolic pathways and inhibiting ATP-consuming
pathways and is a good target for the treatment of T2D (Viollet et al., 2006).
Metformin is used in the treatment of T2D and activates AMPK in hepatocytes,
which in turn suppresses lipogenic genes, such as SREBP1c and Acetyl-CoA
carboxylase (ACC) (Viollet et al. 2012; Zhou et al., 2001). 5-aminoimidazole-4carboxamide-1-beta-D-ribofuranoside (AICAR), an AMPK activator, also
reversed alcoholic fatty liver in rats (Tomita et al., 2005). Both Metformin and
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AICAR act on AMPK to provoke similar effects to increase ATP-producing
pathways and elicit beneficial results (Zhou et al., 2001; Tomita et al., 2005).
Perfluorinated chemicals (PFCs) have been studied for a couple of decades
and have multiple detrimental effects in rodents (Lau et al., 2007).
Specifically, PFOS, According to the Environmental Protection Agency (EPA),
PFOS is considered to be a hepatotoxicant and obesogen and possible
carcinogen in humans. There are limited data regarding PFOS effects in
human related to NAFLD or liver effects. The C8 Health Project, which has
studied a cohort of about 47,000 human subjects, and reported a positive
correlation between serum PFOS and ALT concentration, suggesting liver
effects (Gallo, 2012).

PFOS administration is described to increase liver

weight, expression of genes in fatty acid oxidation in rodents (Wan et al.,
2012). Moreover, PFOS-induced steatosis has been shown to be dose- and
time- dependent, as observed with increased expression of fatty acid transport
genes, and decreased expression mitochondrial β-oxidation genes (Wan et
al., 2012). Liver weight increases are, in part, attributed to an increase in
hepatic triglycerides (Bijland et al., 2011). The reversibility of PFOS-induced
hepatic lipid accumulation has not been described.

The overall goal of this project was to determine whether PFOS exposure
interferes with recommended therapies to decrease hepatic lipid content that
are used to treat NAFLD. It was hypothesized that PFOS administration could
interfere with the benefits of CR and metformin potentially through targeting
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AMPK phosphorylation.

Overall, we present novel findings illustrating that

PFOS administration concurrent with a modest reduction in caloric intake
thwarted CR-induced decline in hepatic lipids and improvement in glucose
tolerance and interfered with metformin-induced glucose lowering effects in
vitro.
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MATERIALS AND METHODS
Animals. 10-week-old male C57BL/6 mice weighing approximately 30 grams
were purchased from Charles River Laboratories (Wilmington, MA). The mice
were housed under a controlled temperature (70-73F) with relative humidity
(30-70%), lighting (12 h, light-dark cycles) environment and acclimated for 5
weeks on the standard rodent chow to allow for additional weight gain. At 15
weeks of age, the mice were then fed a purified rodent chow (AIN-93G Growth
Purified Diet, TestDiet, St. Louis, MO) and monitored for an additional 5 weeks
for food consumption to calculate a 25% calorie restriction. At 21 weeks of
age, mice were fed either ad libitum (AL) or placed on a 25% caloric restriction
(CR). The mice were then divided into two subsequent groups (n=8) that were
administered tap water as vehicle (Veh) via oral gavage (5 ml/kg) or
Heptadecaperfluorooctanesulfonic acid (PFOS) potassium salt (100 µg/kg, 5
ml/kg) purchased from Sigma Aldrich (catalog#77282, Lot#BCBH2834V, St.
Louis, MO) for 6 weeks. Body weight and food intake were monitored daily
and recorded. Serum, liver, white adipose tissue, and skeletal muscle from
non-fasted mice were collected, snap frozen with liquid nitrogen, and stored at
-70°C until analysis.

Glucose tolerance test and insulin tolerance test. Glucose tolerance (GTT)
and insulin tolerance tests (ITT) were performed as previously described
(More et al., 2013; Xu et al., 2012). The GTT and ITT were performed after 3
and 4 weeks of CR and PFOS treatment, respectively. For the GTT, mice
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were fasted for 12 hours and glucose (1 g/kg, i.p.) was administered. For ITT,
mice were fasted for 12 hours and insulin (1 unit/kg, i.p.) was administered.
Blood glucose was determined by measuring tail blood concentrations at 0,
15, 30, 60, and 120 min after glucose or insulin administration using a Bayer
Contour glucometer.

Measurement of cholesterol, triglyceride, free fatty acid, and glucose
concentration. Cholesterol, triglyceride, and, free fatty acid quantifications
were performed using colorimetric assay kits from Pointe Scientific Inc.
(Canton, MI) according to the manufacturer’s protocol. Tissues (50 mg) were
homogenized with PBS and extracted with chloroform-methanol (2:1; vol/vol).
The residue was re-suspended in 1% Triton X-100 in 100% ethanol. Lipid
content was normalized with tissue weight. Serum glucose concentration was
measured with a glucose assay kit (Eton Bioscience Inc., San Diego, CA)
based on manufacturer’s protocol.

RNA isolation and quantitative real-time PCR. Total RNA was isolated using
TRIzol reagent (Invitrogen, Camarillo, CA) according to the manufacturer’s
instructions. 1 μg of total RNA was converted to cDNA, and mRNA levels were
quantified by quantitative real-time PCR using a Roche LightCycler 480
System (Roche Applied Science, Mannheim, Germany). SYBR green reagent
was used, and relative target gene expression was normalized to GAPDH
mRNA.
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Determination of relative protein expression in liver and skeletal muscle by
western blot. Tissues (∼50 mg) were homogenized in 1 ml of RIPA buffer
containing protease and phosphatase inhibitor.

Protein lysates were

electrophoretically resolved using polyacrylamide gel electrophoresis (SDSPAGE). Proteins were resolved by SDS-PAGE (10% resolving and 4%
stacking gel) and then transblotted onto low fluorescence polyvinylidene
fluoride membrane (PVDF) (Millipore, Billerica, MA) in transfer buffer at 30V
overnight. Antibody blocking conditions, dilutions, incubation conditions, and
secondary antibodies are described in a supplemental table (Supplemental
Table 1). PVDF membranes were incubated in blocking solution for 1 hour.
Next, blots were incubated with primary antibody specific to the protein of
interest diluted in blocking buffer at either 4°C overnight or room temperature
for 3 hours. Primary antibody was removed and the membrane was washed
with washed in tris-buffered saline with 0.2% Tween 20 (TBS/T) three times for
5 min at room temperature. Next, blots were incubated with secondary
antibody specific diluted in blocking buffer for 1 hour. The membrane was
either visualized if infrared detection was used (LiCOR Odessey, Lincoln,NE)
or incubated in ECL+ chemiluminescent substrate for 5 min (GE Healthcare
Life Sciences, Pittsburgh, PA) and visualized using light-sensitive film. The
relative abundance of protein in each sample was quantified and normalized to
β-actin.
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Primary hepatocyte and HepG2 treatment and assay for glucose production.
Primary mouse hepatocyte isolation.

Primary mouse hepatocytes were

isolated from livers of adult C57BL/6 mice using a two-step collagenase
perfusion; 1x106 cells/well in 2 mL completed medium (William’s Medium E
supplied with 10% FBS) were seeded on collagen-coated 6-well plates. After
cell attachment (~4 h), they were cultured in serum-free William’s E Media
containing

1%

insulin-transferrin-selenium

(ITS)

and

dexamethasone

supplement (Invitrogen, CA). Media was then replaced with custom William’s
Media E lacking glucose and supplemented with pyruvate.

Media was

collected at time zero to measure glucose output. Glucagon (100nM), PFOS
(2.5 µM) or a combination of both, were added to the hepatocytes and media
was collected at 6 hours to measure glucose output using a glucose assay
(Eton Bioscience Inc., San Diego, CA). HepG2 cells were treated with PFOS
(25, 50, and 100 µM), and metformin (1mM) alone or in combination. Media
was collected after 6-10 hours after treatment and media glucose
concentration was assayed using the glucose assay described above.

Adiponectin assay. The Mouse Adiponectin/Acrp30 Quantikine ELISA Kit was
purchased from R&D Systems, Minneapolis, MN. The protocol followed was
according to the product insert. Mouse sera was diluted 1:2000 and media
from cultured adipocytes was diluted 1:2000 before running in the assay.
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Oil-Red-O Staining. Cells were fixed with 10% buffered formalin for 30 min and
then stained with Oil red O (ORO) working solution. A fresh working solution
was prepared by combining 3 parts of stock solution (0.5% ORO in
isopropanol) with 2 parts of deionized water and then filtered after 15 minutes.
Cells were incubated in working solution for 15 min at room temperature and
then ORO solution was removed. Wells were quickly rinsed 2 times with fresh
60% isopropanol, washed with water, and mounted in glycerin jelly.
Quantification includes the addition of 1mL isopropanol to each well then
140uL of those wells into a 96-well plate for spectrophotometer reading.

Statistical Analysis.
Power

analysis

using

the

sample

size

calculator

http://www.jerrydallal.com/LHSP/SIZECALC.HTM was performed with the
following assumption that the difference in mean between the test and control
group is 50% of the mean and the standard deviation is 25% of the mean
values.

Based on this analysis, the sample size used was an n = 8.

Depending on the analysis, an unpaired Student’s T-test was used or an
ANOVA followed by a Duncan’s Multiple Range Post Hoc Test. Significance
was considered to be p<0.05.
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Results
Effect of CR and PFOS on body weight, liver weight, and serum
chemistry.

21-week old male C57BL/6 mice were fed ad libitum or 25%

calorically restricted for 5 weeks.

In each group, mice were administered

vehicle (VEH) or 100 µg/kg PFOS daily. In Figures 1a and b, CR reduced the
percent body weight from day 0 and the AUC for body weight over time. Body
weight and percent weight loss was similar between VEH and PFOS treated
mice over the course of the study. CR decreased liver weight by 37.4% and
WAT tissue by 48.2% (Figures 1C & D). Liver and WAT weight was similar
between VEH and PFOS treated groups. Overall, PFOS administration did
not significantly alter body or tissue weight, as well as response to CR-induced
weight loss.
Serum clinical markers associated with response to weight loss and CR were
evaluated (Table 1). CR increased adiponectin levels by 24.2% compared to
AL fed mice. In AL fed mice, PFOS also increased adiponectin by 23.4%. In
CR fed mice, PFOS did not significantly affect serum adiponectin levels. CR
decreased serum glucose by 29.6% compared to AL fed mice. Interestingly,
in AL fed mice, PFOS increased serum glucose levels by 65.3% compared to
AL control. In CR fed mice, PFOS increased serum glucose levels by 67.3%
compared to CR mice administered vehicle.
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PFOS interfered with CR-induced improvement of glucose utilization.
CR improves glucose tolerance and increases insulin sensitivity (Colman et
al., 2009; Fontana, 2009). The effect of PFOS on this CR-induced benefit was
evaluated. CR decreased glucose levels over time (Figures 2a and b). Overall,
CR decreased glucose load by 57.9% compared to AL fed mice (Figure 2c).
In AL fed mice, PFOS administration did not significantly affect response to
glucose challenge, although the glucose load tended to increase, but did not
reach statistical significance (p=0.8938) (Figures 2a-c). Interestingly, PFOS
administration did affect the response to glucose challenge in mice that were
placed on CR, with glucose clearance being decreased in CR mice
administered PFOS (Figure 2a and b). Compared to CR mice administered
VEH, glucose load was 74.3% higher in CR mice administered PFOS (Figure
2c). In CR and AL fed mice, PFOS significantly increased the glucose load
after 2.5 hours after insulin challenge compared to controls (Figure 2d),
suggesting that PFOS interferes with insulin suppression of hepatic glucose
production. Glucose homeostasis hepatic gene expression was analyzed by
qPCR. CR did not markedly decrease Irs1 gene expression levels, however,
with PFOS, CR fed mice significantly decreased Irs1 gene expression (Figure
2e).

CR fed mice had decreased hepatic gene expression of Pepck and

G6pase compared to AL controls (Figure 2e). In both CR and AL fed mice,
PFOS significantly decreased Glut2 gene expression (Figure 2e).

Protein

quantification of phosphorylated-akt was measured within the lysates of
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skeletal muscle of these mice. PFOS had no affect on p-akt in either CR or AL
fed mice (Figure 2f).

PFOS significantly increased lipid content in the livers of mice.
It has been previously reported that PFOS increased liver weight (Seacat et
al., 2002; Seacat et al., 2007) and this may be attributable to an accumulation
of lipids within the liver (Polyzos et al., 2009). We evaluated the liver histology
with hematoxylin and eosin (H&E) staining.

CR There is the presence of

vacuoles in the CR-PFOS treatment group that are not seen in any other
group (Figure 3a). PFOS significantly decreased hepatic free fatty acids (FFA)
by 38.7% in AL fed mice and 39.2% in CR fed mice (Figure 3b). These data
are further supported by the significant increase in triglycerides in PFOStreated mice. As expected, CR fed mice had a significant 31.9% decrease in
hepatic triglycerides compared to AL control (Figure 3c). Interestingly, PFOS
significantly increased hepatic triglycerides in both AL and CR fed mice by
94.9% compared to AL-Veh and 37.6% compared to CR-Veh, respectively
(Figure 3c). CR fed mice significantly increased hepatic gene expression of
Cyp4a14 compared to AL fed control (Figure 3d).

PFOS significantly

increased gene expression in the liver of Cyp4a14 in AL and CR fed mice
compared to controls (Figure 3d).

PFOS significantly decreased Ppar-α

hepatic gene expression in both AL and CR fed mice compared to controls
(Figure 3e). Downstream targets of Ppar-α were increased upon CR with
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significant induction of Gpat hepatic gene expression with PFOS exposed CR
fed mice (Figure 3e).

PFOS alters glucose homeostasis protein expression of mice.
To better understand whether PFOS was affecting response to CR at the level
of protein expression, liver lysates were evaluated for changes in protein
expression. Western blot analysis of proteins involved in glucose and lipid
homeostasis was measured (Figure 4a and b).

CR fed mice with PFOS

administration protein levels were compared to CR fed mice with vehicle
(Figure 4a). Phosphorylated-akt is responsible for the uptake of glucose into
cells and is significantly decreased 38.4% upon PFOS administration in mice
that underwent CR compared to CR control (Figure 4c). Conversely,
Phosphoenolpyruvate carboxykinase (Pepck) is the main regulator of
gluconeogenesis and is significantly increased, both supporting the glucose
data in Figure 2 (Figure 4c). Protein levels of P-ampk decreased significantly
by 34.2% upon PFOS administration with CR compared to control (Figure 4c).
Protein levels in all groups were compared (Figure 4b).

Cluster of

differentiation (CD36), also known as fatty acid translocase (FAT), and fatty
acid synthase (Fas) both increased significantly upon PFOS exposure with CR
fed mice by over 2-fold and 2.5-fold, respectively, compared to CR control
(Figure 4d). Astoundingly, P-ampk significantly decreased over 7-fold in mice
that underwent CR with PFOS administration compared to CR control (Figure
4d).
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PFOS significantly increased glucose within the media of Primary
Hepatocytes and HepG2 cells.
Based on our GTT observations, and changes in P-AMPK in liver, the effect of
PFOS on glucose production in hepatocytes was measured.

Primary

hepatocytes were isolated from C56BL/6 mice and were treated with
glucagon, PFOS (2.5uM) and a combination of both for 24 hours.

PFOS

increased glucose levels in media of primary hepatocytes eliciting a glucagonlike effect.

Expectedly, glucagon increased glucose within the media of

HepG2 cells 13-fold compared to vehicle (Figure 5a). PFOS also increased
the glucose within the media by 15-fold and taken together, PFOS and
glucagon treatment increased the glucose within the media by 19.6-fold
compared to vehicle (Figure 5a). HepG2 cells were treated for 10 hours with
Metformin (1mM), PFOS (25uM or 100uM) and a combination of both.
Metformin significantly decreased glucose production in the media of HepG2
cells by 67.2% compared to DMSO control (Figure 5b).

PFOS (100uM)

significantly increased glucose within the media by 3.2-fold compared to
DMSO control (Figure 5b).

When challenged with metformin, PFOS still

induced glucose output into the media of HepG2 cells by 7-fold compared to
metformin control (Figure 5b), illustrating that PFOS dampens the Metformininduced lowering of glucose within the media. In a dose-response study with
HepG2 cells, 5-aminoimidazole, 4-carboxamide ribonucleotide (AICAR) was
used to stimulate phosphorylation of AMPK and challenged with different
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concentrations of PFOS (Figure 5c). PFOS increased glucose production at
25uM 6-fold compared to DMSO control (Figure 5c).

PFOS (25uM) with

AICAR increased glucose within the media by 3.5-fold compared to AICAR
control (Figure 5c).

P-ampk protein levels were analyzed by western blot

analysis from the lysates of data in Figure 5b. Metformin increased p-ampk
while PFOS (25uM) decreased p-ampk protein levels.

When treated with

metformin and PFOS (25uM), p-ampk levels are greatly decreased compared
to metformin control (Figure 5d).

PFOS increases glucose within the media of 3T3L1 cells and human
adipocytes.
Mature adipocytes were treated with Metformin (1mM) and PFOS (50uM) or in
combination for 12 hours. PFOS significantly increased glucose within the
media of these cells compared to the DMSO control (Figure 6a). Although
there is an increasing trend of PFOS with metformin, this is not statistical
(Figure 6a). Adiponectin levels were also measured, however, no changes
were observed among groups (Figure 6b). Human adipocytes were treated
with Metformin (1mM), PFOS (50uM) or in combination for 24 hours (Figure
6c). PFOS showed an increasing trend of glucose within the media, however
this is not statistical.

PFOS in combination with Metformin significantly

decreased the glucose in the media of these cells compared to DMSO control
(Figure 6c). Oil-Red-O staining of human adipocytes shows more lipids with
PFOS treatment compared to DMSO control (Figure 6d).
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Discussion
NAFLD is a rising worldwide and is associated with obesity and diabetes
(Masarone et al., 2014). Diabetes and NAFLD predict the development of one
another and create a cycle of progression from NAFLD to diabetes and vice
versa (Williams et al., 2013). NAFLD is characterized by >5% of the liver
made up of fat, lipotoxicity and insulin resistance and thus frequently found in
people with central obesity or diabetes (Naik et al., 2013; Smith and Adams,
2011). Fatty liver is a status of insulin-resistance and responds to treatments
originally developed for other insulin-resistant states such as Metformin (Ford
et al., 2015). Obesity is considered to be a predominant risk factor for NAFLD,
however other etiologies for NAFLD have been hypothesized, such as
environmental factors (Cave et al., 2007). The purpose of this study was to
evaluate whether, PFOS, an environmental chemical associated with adverse
liver effects would affect the recommended therapeutic strategy to treat
NAFLD. Our findings herein illustrate that PFOS dampened the response to
CR and interfered with metformin-induced glucose consumption.
The most beneficial treatment of NAFLD is a low-fat diet and exercise
(Chalasani et al., 2012). In earlier studies, it is suggested that CR with or
without exercise decreases liver fat and liver enzymes with no difference
between CR groups with the CR and exercise groups (Yoshimura et al. 2014;
Straznicky et al., 2012; Tamura et al., 2005; Larson-Meyer et al., 2008). It has
been reported that a 15, 30 and 40% kCal reduction in mice has beneficial
implications on body weight and hepatic lipids (Zidong and Klaassen, 2013).
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In our study, mice were placed on a 25% kCal reduction or fed ad libitum for 5
weeks dosed with vehicle or challenged with 0.1mg/kg/day PFOS.
Expectedly, our results are consistent with other studies showing significant
decreases in body, liver and WAT weights with a ~25%kCal reduction
(Weindruch et al., 1986; Zidong and Klaassen, 2013) which is on the lower
side of a kCal reduction (ranges from ~25-60%) (Koubova and Guarente,
2003). Our glucose tolerance test (GTT) provides evidence for CR increasing
glucose tolerance and lowering the total glucose load within mice as well as
significantly decreasing serum and hepatic lipids CR and these results are
consistent with other studies (Zidong and Klaassen, 2013). AMPK inhibits
hepatic glucose and lipid synthesis and induces lipid oxidation to produce
energy (Nerstedt, 2010). AMPK is a regulator of hepatic metabolism in energy
balance by promoting catabolic pathways and inhibiting ATP-consuming
pathways and is a good target for the treatment of Type II diabetes (Viollet et
al., 2006). AMPK activation is implicated for the benefits of glucose and lipid
metabolism with exercise, weight loss, and use of anti-diabetes drugs (Towler
et al., 2007). Expectedly, in our study, CR induced AMPK activation in mice
compared to AL control. AMPK is a heterotrimeric serine/threonine protein
kinase that regulates energy homeostasis in metabolic tissues upon high
AMP:ATP ratios (Nerstedt, 2010).
It is known that PFCs elicit fatty liver, but fewer studies address effects of
PFOS on hepatic lipid accumulation. To the best of our knowledge, this is the
first study that has investigated the effects of PFOS on the role of Metformin
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and AMPK in a calorically restricted diet. Here, we show that a daily dose of
PFOS for over five weeks dampens the beneficial lipid loss of CR as well as
decreasing the ability of Metformin to lower glucose production via AMPK.
PFOS exposure has been shown to increase serum glucose and insulin levels,
although not statistically (Wan et al., 2014). Wan et al. also show a prediabetic phenotype within mice exposed to PFOS (Want et al., 2014). We
show the same trend where PFOS exposure leads to increasing glucose
within the serum of in vivo and in vitro models. IRS-1 gene expression was
significantly decreased upon PFOS exposure in mice undergoing CR
compared to our ad libitum mouse model.

Glut-2 gene expression was

significantly decreased in both CR and AL mouse models upon PFOS
exposure, which may be due to glucose-intolerance as seen with the GTT. In
this study, we used the C57BL/6 mouse model on a purified diet that
underwent CR and daily administration of PFOS to assess the effects of PFOS
on a CR diet via liver physiology. We recognize that this model is in lean mice
and is not a true clinical representation of individuals undergoing CR and an
obese mouse model would be the better representation of studying PFOS
effects on NAFLD compared to CR mice with PFOS exposure to truly assess
PFOS liver physiology. PFOS has been shown to increase body and liver
weight but has also elicited effects in models in which did not show an
increase in body or liver weight (Ngo et al., 2014; Nelson et al., 2010). A study
showed a decrease in body weight but an increase in liver weight with PFOS
exposure (Seacat et al., 2003). Another study showed increased body weight
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at a lower concentration of 1 mg/kg and increased body weight at higher
concentrations of 5 and 10mg/kg over 21 days with all concentrations
increasing the liver weight attributed to the appearance of cellular vacuolations
(Wan et al., 2012; Kim et al., 2011). In our model, a sub-chronic dose of
PFOS did not affect the body or liver weights of mice with or without CR.
PFOS has been shown to have a positive correlation with serum ALT levels
(Gallo, 2012) and increased liver weights (Seacat et al., 2014), which may be
attributable to an accumulation of lipids. Associations have been made here
PFOS has increased the number and size of cytoplasmic vacuoles as well as
and increase in lipid content, concluding the vacuoles contain lipids (Wan et
al., 2012).

In our study, we show PFOS increasing hepatic triglycerides,

interfering with the CR-induced lipid loss. H&E staining shows PFOS with CR
induces the presence of vacuoles compared to any other group and it is
reasonable to assume that these vacuoles contain lipids.

PFOS induces

PPAR-α, which is suggested to account for toxicity associated with PFOS
(Takacs and Abbott, 2007), however, there are PPAR-α independent toxicities
as well (Rosen et al., 2010). We show induction of CYP4a14, a downstream
target of PPAR-α, upon PFOS exposure.

We used Metformin as a treatment in in vitro models because it is used in the
treatment of Type II diabetes and has been shown to activate AMPK (Zhou et
al., 2001). We show that PFOS dampens the beneficial effects of Metformin
on lowering glucose production via AMPK activation. Our results indicate that
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PFOS can potentially interfere with AMPK phosphorylation in liver and cells,
which is relatively new to the field of environmental health. For example, we
observed that glucose production was increased in HepG2 cells and
hepatocytes treated with PFOS.

AMPK suppression is known to induce

gluconeogenesis via LKB1 down-regulation (Shaw et al., 2005). In a study,
genetic silencing of LKB1 resulted in nearly a complete loss of AMPK activity
(Shaw et al., 2005), suggesting LKB1 is necessary for AMPK activation.
PFOS is suggested to be transported into the liver via Oatp2 or Oatp1d1
(Popovic et al., 2014; Yu et al., 2011). The primary transporters required for
hepatic uptake of Metformin are OCT1 and OCT3 (Zheng et al., 2014). PFOS
and Metformin do not utilize the same transporters, suggesting that PFOS may
inhibit beneficial effects of Metformin downstream.
Glucose in the media of primary hepatocytes was statistically increased upon
PFOS and glucagon exposure. Metformin significantly decreased glucose in
the media while PFOS (100 µM) significantly increased media glucose in
HepG2 cells after 10 hours of exposure. A combination of Metformin and
PFOS 100 µM was increased compared to Metformin alone. Both Metformin
and AICAR act on AMPK to elicit similar effects to decrease ATP-consuming
pathways and increase ATP-producing pathways (Zhou et al., 2001; Tomita et
al., 2005). Both PFOS (25 µM) and AICAR in combination with PFOS (25 µM)
significantly increase glucose in media compared to DMSO control in HepG2
cells. AICAR with PFOS (25 µM) significantly increases glucose in media
compared to AICAR alone. P-AMPK protein levels were measured in HepG2
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cells treated with PFOS (25 and 50 µM) and Metformin (1mM) where PFOS
decreases P-AMPK protein levels when co-treated with Metformin, diminishing
beneficial effects of Metformin.
In our study, we present novel findings illustrating that PFOS
administration concurrent with a modest reduction in caloric intake thwarted
CR-induced decline in hepatic lipids and improvement in glucose tolerance
and interfered with metformin-induced glucose lowering effects in vitro. To the
best of our knowledge, this is the first study that investigates PFOS effects on
metformin and AMPK in a calorically restricted diet. Our results indicate novel
findings of lowered AMPK levels upon PFOS administration as well as PFOS
interference with a major pharmacological therapeutic for diabetic intervention.

Conclusion
Perfluorooctanesulfonic acid, a fluoro-surfactant previously used as a
stain repellent and anti-stick material increased hepatic lipids in mice following
relatively low dose exposures. An increase in hepatic lipids leads to nonalcoholic fatty liver disease.

A combination of caloric restriction, dietary

modification, and exercise is the recommended therapy to reverse obesity and
nonalcoholic fatty liver disease. The ability to mount an effective response to
caloric restriction required to effectively shift hepatic metabolism to fatty acid
oxidation depends upon induction of pathways, such as AMP- activated kinase
(AMPK). We hypothesized that PFOS administration will interfere with CRinduced reduction of hepatic lipids and improve glucose tolerance.
Throughout our studies, we found that PFOS increases hepatic lipid content
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and decreases the ability of mice to effectively decrease this lipid content upon
CR intervention. In vitro studies have shown that PFOS interferes with CR
when challenged with Metformin and decreases the ability of Metformin to
reduce glucose within the media. PFOS decreases the beneficial effects of a
calorically restricted diet and interferes with Metformin’s glucose lowering
effects.
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J Haz

Figure 1. Adult male mice were administered vehicle (Water, VEH) or
perfluorooctane sulfonate (PFOS, 0.1mg/kg/day) and fed ad libitum (AL) or
placed on 25% kCal caloric restriction (CR) for approximately 6 weeks. (A)
Percent change (%) in body weight from day 0 and (B) the AUC of percent
body weight illustrate that PFOS did not significantly alter CR-induced percent
weight at the time of necropsy. In mice that underwent CR, (C) Liver weight
and (D) white adipose tissue (WAT) weight were not statistically different upon
PFOS administration compared to vehicle. Groups without a common letter
are statistically different (p<0.05).

Figure 2. Effect of PFOS and CR on glucose homeostasis. (A) Raw glucose
tolerance test (GTT) data and (B) percent change (%) in glucose compared to
time 0. CR significantly improved glucose clearance at 0.5 and 1 hours, which
did not occur in mice that underwent CR with PFOS administration. (C) Total
glucose load of GTT plotted as an area under the curve (AUC).

PFOS

significantly increased total glucose load in CR groups. (D) Raw data of the
insulin tolerance test (ITT).

The glucose load was not different between

groups until 2.5 hours where the two PFOS groups had significantly higher
glucose load compared to controls. (E) Hepatic mRNA data. Irs-1 and Glut2
expression are significantly decreased in mice that underwent CR upon PFOS
administration. Glut2 expression was significantly decreased in ad libitum with
PFOS compared to control. (F) PFOS did not markedly alter phosphorylated
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akt protein levels in these mice. Asterisks (*) represent a statistical difference
in treatments groups compared to controls.

Figure 3.

PFOS significantly increased hepatic lipid content.

(A) Liver

histopathology. H&E staining of liver tissue illustrates PFOS increase
vacuolization in mice that underwent CR compared to control. Hepatic (B) free
fatty acids (FFA) were statistically decreased upon PFOS administration. (C)
Hepatic triglycerides were statistically increased upon PFOS administration.
(D) Hepatic mRNA of cyp4a14 and (E) ppar-α and downstream targets.
Cyp4a14 was statistically induced in mice that underwent CR and PFOS
administration compared to control.

Groups without a common letter are

statistically different.

Figure 4. Hepatic protein expression and quantification. (A) Western blots of
proteins involved in glucose homeostasis and lipogenesis in mice that
underwent CR. (B) Western blots of proteins involved in the CR pathway. (C)
PFOS significantly decreased phosphorylated akt protein levels while
significantly increasing pepck protein levels in mice that underwent CR
compared to control. (D) PFOS significantly decreased p-ampk in mice that
underwent CR compared to control. Asterisks (*) represent groups that are
statistically significant compared to control.
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Figure 5. In vitro glucose and protein measurements in primary hepatocytes
and HepG2 cell lines.

(A) Media glucose measurement in primary

hepatocytes with treatments of 6 hours with glucagon, PFOS (2.5uM), and in
combination. PFOS statistically increased glucose in the media of primary
hepatocytes. (B) Media glucose measurement in HepG2 cells with treatment
of 10 hours with Metformin (1mM), PFOS (25 and 100uM), and a combination
of Metformin with both concentrations of PFOS.

Metformin significantly

decreased glucose in the media while PFOS100uM significantly increased
glucose.

A combination of Metformin and PFOS100uM was significantly

increased compared to Metformin alone. *, p<0.05, Metformin compared to
DMSO; PFOS100um compared to DMSO.

#, p<0.05, PFOS100uM +

Metformin compared to Metformin alone. (C) Media glucose measurement in
HepG2 cells with treatments of 24 hours with AICAR (100uM), PFOS
(0.025uM-25uM) and a combination of AICAR with each PFOS concentration.
Both PFOS 25uM and AICAR with PFOS25uM significantly increase glucose
in media compared to DMSO control. AICAR with PFOS25uM significantly
increases glucose in media compared to AICAR alone. *, p<0.05, PFOS25uM
and AICAR compared with DMSO control. #, p<0.05, AICAR with PFOS25uM
compared to AICAR alone. (D) Western blot of P-ampk (n=1) of HepG2 cells
treated with PFOS (25 and 50uM) and Metformin (1mM). PFOS decreases pampk protein expression when co-treated with Metformin, diminishing
beneficial effects of Metformin.
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Figure 6. Analysis of glucose homeostasis in mature adipocytes and human
adipocytes. 3T3L1 cells were treated with Metformin (1mM), PFOS (50uM)
and a combination. (A) Media glucose of mature 3T3L1 cells was significantly
increased upon PFOS treatment.

(B) PFOS significantly increased

adiponectin levels in mature adipocytes upon PFOS treatment compared to
control. (C) Human adipocytes were treated with DMSO, Metformin (1mM),
PFOS (50uM), and a combination of PFOS with Metformin. PFOS increased
the glucose in the media of these cells (p<0.06) and significantly decreased
glucose when treated in combination with Metformin. Asterisks (*) represent a
significant difference compared to control.
human adipocytes. Mag.10x.
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(D) Oil-Red-O staining of the

Table 1. Serum Metabolic Measurements.

Adiponectin, cholesterol, free fatty acids, glucose and triglycerides

measurements of mice after euthanization.
Parameters

Unit

AL-VEH

CR-VEH

AL-PFOS

CR-PFOS

Adiponectin

ng/ml

11007.34±596.02

13674.87±459.70*

13579.57±974.31$

13565.01±668.01#

Cholesterol

mg/dl

120.01±10.92

108.45±14.85

113.95±10.46

98.19±4.64

FFA

μmol/l

0.96±0.15

1.10±0.11

1.15±0.35

1.06±0.10

Glucose

ng/ml

3744.83±155.85

2637.29±210.06*

6189.69±394.14$

4414.46±162.14#,§

Triglycerides

mg/dl

172.08±42.49

130.89±17.00

154.63±17.31

137.50±4.31
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Eighteen-week old C57Bl/6 mice underwent treatment for approximately six weeks of either water (VEH) or
Perfluorooctanesulfonic acid (PFOS) administration (0.1mg/kg/day) and fed either ad libitum (AL) or underwent 25% kCal
caloric restriction (CR).

After euthanization, these parameters were assayed and analyzed.

*, p<0.05, CR-VEH

compared to AL-VEH control. $, p<0.05, AL-PFOS compared to AL-VEH control. #, p<0.05, CR-PFOS compared to ALVEH control. §, p<0.05, CR-PFOS compared to CR-VEH control.
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ABSTRACT: Perfluorooctanoic acid (PFOA) is a perfluorinated carboxylic acid
commonly found in the environment. According to the EPA, low levels of
PFOA are detectable in the environment and in the blood of the general
United

States

population.

PFOA

administrations

cause

liver

and

developmental toxicity in rodents and is found in serum and tissues of wildlife
and humans worldwide. PFOA is a potent activator of peroxisome proliferator
receptors (Ppars) contributing to oxidative stress and fatty acid oxidation
pathways in hepatocytes and possibly in adipose tissue (ppar-γ). Since PFOA
is extremely ubiquitous and persistent, our hypothesis is that it would increase
gene expression in adipose tissue of mice in regard to fatty acid oxidation, lipid
synthesis and antioxidant response. Adult male mice were treated with 1.0 or
3.0 mg PFOA/kg in corn oil for 7 days. Adipose tissue was collected and total
RNA was isolated. Analysis of mRNA was completed by quantitative PCR.
mRNA expression between control and PFOA treated mice was similar. Our
results indicate PFOA has no affect on adipose tissue of mice after a 7-day
treatment. Literature is lacking information regarding PFOA effects in adipose
tissue.
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INTRODUCTION
Perfluorooctanoic acid (PFOA) is a synthetic surfactant and is
expressed in sera throughout the world of humans and animals (EPA, 2009a;
and Hines, et al. 2009). PFOA is used in the manufacturing process to make
fluoropolymers with specific properties for various industrial applications
including fire resistance, water, oil, and grease repellency as well as providing
non-stick surfaces for cookware (EPA, 2009a). PFOA is also produced from
the breakdown of fluorinated telomers such as grease, soil, stain and water
resistance (EPA, 2009a).

The Environment Protection Agency (EPA) is

investigating PFOA as a possible toxin to humans due to the presence of an
closely related PFC, perfluorooctyl sulfonates (PFOS), in the blood of the
general United States population which raised concern for its persistence in
the environment, bioaccumulation and toxicity in the late 1990’s (EPA, 2009a).
Manufacturing of PFOS ceased and the EPA started investigating similar
chemicals that might elicit comparable apprehensions (EPA, 2009a). PFOA
has been investigated since the 1990’s and is known to elicit liver effects
(hepatomegaly), development toxicant, and carcinogen in rodent models and
found in serum and tissues of wildlife and humans worldwide with an average
half-life of 3.5 years in humans (EPA, 2009a; Hines, et al. 2009; Klaunig, et al.
2003; Tardiff, et al. 2009). PFOA stimulates similar effects to peroxisome
proliferating chemicals (PPC), which have been shown to provoke liver cancer
due to the induction of peroxisome proliferater-activated receptor alpha
(PPAR-alpha) (Rosen, et al. 2008b). Calafat et al suggests that men have
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higher serum concentrations of perfluoroalkyl acid’s (PFAA) than women, and
the younger population has higher concentrations than the older population
(Calafat, et al. 2007). In Danish men, Joensen et al found that higher PFAA
concentration is associated with fewer normal spermatozoa (Joensen, et al.
2009). PFOA can cross the placental membrane and has been found in
umbilical cord blood in levels that are negatively associated with newborn
weight (Apelberg, et al. 2007). Human studies of PFOA are limited, however,
trace amounts of PFOA have been detected in seminal plasma samples, cord
blood, and low levels in urine associated with high levels of biliary reabsorption
rates, (Apelberg, et al. 2007; Harada, et al. 2007; and Joensen, et al. 2009).
Maestri et al found 0.1ng/g PFOA in all human tissue except for adipose
tissue, where it was 0.2ng/g PFOA in the general population with very low
exposure of PFOA (Maestri, et al. 2006).
Since there is cross-talk among the liver tissue with peripheral tissues, if there
are effects within the liver, then these effects may also affect adipose tissue.
Some interconnecting enzymes include sterol regulatory element binding
protein 1 (SREBP1) regulates which genes involved in lipid biosynthesis
including fatty acid synthetase (FAS) and acetyl co-A carboxylase (ACC1)
involved in de novo lipogenesis, diacylglycerol acetyltransferase (DGAT),
glycerol-3-phosphate acyltransferase (GPAT) and lipoprotein lipase (LPL)
involved in the reesterification of fatty acids, and stearoyl co-A desaturase
(SCD1) involved in fatty acid desaturation and elongation (Hagen, et al. 2010).
Peroxisome proliferator-activated receptor alpha (PPAR-alpha) is found
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predominantly in the liver and is involved in lipid and lipoprotein metabolism
reducing triglyceride levels as well as maintaining energy homeostasis
regulating obesity (Tyagi, et al. 2011).

PPAR-gamma targets LPL and is

involved in lipid metabolism and lipid uptake into the adipocytes and is
involved in adipocyte differentiation and hypertrophy (Tyagi, et al. 2011).
Ppar-y is highly expressed within adipose tissue and may be an unrecognized
target for various industrial or environmental chemicals within society, such as
PFOA (Malone and Waxman, 1999).
Nuclear factor-2 p45 related factor 2 (NRF2) is a basic leucine-zipper
transcription factor that serves as a cellular detoxicant by positively regulating
over 200 cytoprotective genes that defend against stressors, such as toxic
chemicals and radiation (Klaassen, et al. 2010; Niture, et al. 2011; Sykiotis, et
al. 2011; Young-Sam, et al. 2006).

The genes include phase II drug

metabolizing enzymes and antioxidant proteins (Young-Sam, et al. 2006).
NRF2 is sequestered in the cytoplasm via Kelch-like ECH-associated protein
(Keap1) (Giudice, et al. 2010; Young-Sam, et al. 2006). Upon activation by
stressors, NRF2 is released from Keap1 and translocates into the nucleus,
binding to antioxidant response elements (ARE)/electrophile response
elements (EpREs) in the promoter region and eliciting activation of
cytoprotective genes (Giudice, et al. 2010; Niture, et al. 2011; Young-Sam, et
al. 2006). Keap1 travels into the nucleus binding to NRF2 dissociating it from
ARE and the complex is exported to the cytoplasm via the nuclear export
sequence of keap1 (Giudice, et al. 2010).
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Natural and synthetic

chemopreventive agents induce antioxidative and carcinogen-detoxification
enzymes via the NRF2/keap1 pathway (Giudice, et al. 2010). Nrf2 controls
the basal and inducible expression of mouse and human genes, such as
NQO1, GCLC, and GSTA1 (Klaassen, et al. 2010; Ramos-Gomez, et al.
2001). Oxidative stress is a stressor that activates nrf2/keap1 pathway and
has been linked to insulin resistance due to the increase in mitochondrial
reactive oxidative species (ROS) (Yu, et al. 2012). ROS oxidizes cysteines of
the keap1 dissociating it from nrf2 allowing the translocation of nrf2 to the
nucleus (Ray, et al. 2012). When Nrf2 is activated by known activators on a
high-fat diet, the increase in adipose tissue mass, hepatic lipid accumulation
and body-weight was attenuated (Yu, et al. 2012). However, other studies
have found conflicting data. Pi et al. suggest that Nrf2 knockout mice have
decreased fat mass with more small adipocytes and portray diet-induced
obesity resistance.

In this same study, Nrf2 knock out mouse embryonic

fibroblasts (MEF’s) displayed decreased adipogenesis. In the 3T3-LI cell line
and human subcutaneous preadipocytes, Pi et al demonstrated adipocyte
differentiation inhibition with shRNA-mediated nrf2 knockdown possibly
attributing to the association with, and subsequent decrease of, PPAR-gamma
expression (Pi, et al. 2010). Previous data from our lab indicate that in nrf2
deficiency in Lepob/ob (leptin-deficient-obese) mice induced IR and dyslipidemia
while decreasing white adipose tissue mass and preventing hepatic lipid
accumulation indicating a dual role for Nrf2 in metabolic dysregulation (Xu et
al., 2014).
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In this study, adult male mice were treated with 1.0 mg PFOA/kg or 3.0 mg
PFOA/kg in corn oil for 7 days. We hypothesized that PFOA would alter gene
expression in adipose tissue of mice in regard to fatty acid oxidation, lipid
synthesis and antioxidant response.
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MATERIALS AND METHODS
Animals and treatment paradigm
Animal treatment and PFOA dosing we previously used to investigate
effects PFOA in kidney (Aleksunes, et al. 2013). Briefly, adult male C57BL/6
mice were purchased from Charles River Laboratories (Wilmington, WA) and
fed a normal rodent chow diet (Aleksunes et al., 2013). The mice were split
into three groups (n=6); control, low dose PFOS (1.0 mg/kg) and high dose
PFOS (3.0 mg/kg). Perfluorooctanoic acid (PFOA) (77262, Sigma-Aldrich, St.
Louis, MO) was administered once per day at a dose volume of 5ml/kg for
seven days. For 1 mg/kg dose, 2 mg PFOA was dissolved in 1 ml deionized
(DI) water. This stock was vortexed and 9 ml of DI water was added to make a
2mg/10 ml solution that was filter sterilized. For 3mg/kg dose, 6 mg PFOA was
dissolved in 1 ml DI water and vortexed. Then 9 ml DI water was added to
make a 6mg/10 ml solution, which was filter sterilized. Organs and tissues
were collected and snap frozen and stored in -80 until RNA analysis.

PCR Assay
Total RNA was isolated from the collected adipose tissue by phenolchloroform extraction with 1.2mL Trizol (Invitrogen, Camarillo, CA)/100mg
tissue according to the manufacturer’s protocol.

RNA concentration were

determined by measuring UV absorbance at 260 nm using NanoDrop™. The
total RNA samples were stored at -80°C until further use for analysis. 1 μg of
total RNA was converted to cDNA, and mRNA levels were quantified by
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quantitative real-time PCR using a Roche LightCycler 480 System (Roche
Applied Science, Mannheim, Germany). Genes measured were Acc-1, Scd-1,
Lpl, Ppar-γ, Srebp-1, Nrf2, Nqo-1, Gclc, Irs-1, Keap-1, and Ahr. SYBR green
reagent was used, and relative target gene expression was normalized to
GAPDH or 36B4 mRNA.

Statistical Analysis
Statistical analyses of differences were performed by Student’s t test. P
< 0.05 was considered statistically significant. Unless otherwise stated, all
data were presented as mean ± SE of five animals.
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RESULTS
PFOA treatment did not affect body weight, however, did increase
liver weight.
PFOA has been suggested to induce body weight gain in mice,
however, in our study, the mice did not have and increased average body
weight compared to the vehicle in either 1.0 mg/kg or 3.0 mg/kg PFOA which
is illustrated in Figure 1. It is suggested that mice with PFOA administration
have increased liver weights due to an accumulation of hepatic triglycerides.
In our study, there was a statistical increase that is dose-dependent. The
white adipose tissue weight was unchanged between groups. Kidney tissue
weights were increased with a treatment of 1.0 mg/kg PFOA compared to
vehicle, but not in the 3.0 mg/kg PFOA treatment.

PFOA treatment did not affect lipid synthesis and accumulation
gene expression in white adipose tissue.
Srebp1c is the regulator of lipid synthesis and acts on its target genes,
Scd1 and Acc1.

As shown in Figure 2, Srebp1c mRNA expression was

significantly increased in both treatment groups, while Scd1 and Acc1 were
not significantly different among treatment groups; however, Scd1 possesses
an increasing PFOA dose-dependent trend.

Ppar-α is involved in fatty acid

oxidation with a downstream target of Cyp4a14. PFOA is suggested to be an
agonist for Ppar-α, however, in white adipose tissue with 1.0 and 3.0mg/kg
PFOA for 7 days, Ppar-α gene expression was not statistically different than
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that of vehicle. PFOA treatment did not significantly alter Cyp4a14 compared
to vehicle. Lpl codes for lipoprotein lipase which is involved in the breakdown
of triglycerides to free fatty acids that can be uptaken into tissues, mainly
skeletal muscle, adipose tissue and cardiac muscle.

PFOA did not

significantly alter Lpl gene expression in either treatment group compared to
vehicle.

PPAR-γ is involved in adipocyte differentiation and was not

significantly altered with PFOA administration.

PFOA treatment did not affect oxidative stress gene expression in
adipose tissue
Oxidative stress mRNA expression is illustrated in Figure 3. The
transcription factor, Nrf2, is sequestered in the cytosol by Keap1 until
phosphorylation where Nrf2 translocates to the nucleus activating the initiation
of transcription of its target genes, Ahr and Gsta1.

Nrf2 is significantly

increased with 1.0 mg/kg PFOA treatment compared to vehicle, however, 3.0
mg/kg PFOA treatment is not.

Downstream targets of Nrf2 were not

significantly

among

different
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treatment

groups.

DISCUSSION
The purpose of this study was to evaluate the effects of PFOA
exposure on adipose tissue. Overall, the findings suggest PFOA does not
markedly affect adipocyte differentiation, lipid synthesis and accumulation, or
oxidative stress response in adipocytes.
PFOA is structurally similar to a fatty acid and acts similarly as it
activates nuclear receptors, binds to transporters and carrier proteins and
interacts with membranes (Post, et al. 2012). PFOA activates PPAR-alpha
and other nuclear receptors (Post, et al. 2012). SREBP-1 was significantly
increased in the 3mg/kg PFOA treated mice.

SREBP-1 regulates genes

involved in lipid biosynthesis such as FAS, SCD-1, ACC-1, and LPL (Hagen,
et al. 2010). SCD-1 and ACC-1 remained unchanged in all treatment groups,
however, elicit increasing PFOA-dependent trends. A recent review suggests
that effects such as obesity and metabolic changes are not evident until long
after PFOA has been eliminated from the body, which may be a factor that our
findings are not statistical, however show slight trends (Post, et al. 2012).
Also, it is suggested that prenatal PFOA exposure is associated with the
increased risk of obesity and metabolic hormone differences in 20-year old
women (Post, et al. 2012).
The increase in body weight of mice in a PFOA-dependent manner
could be due to increases of triglycerides, phospholipids, and cholesterol
accumulation in the liver, which induced fatty liver in mice caused by PFOA
administration (Post, et al. 2012).
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Other studies report findings primarily based on liver tissue. Steenland
et al suggest there is a significant, positive correlation of PFOA and
cholesterol levels (Steenland, et al. 2010). Although the mode of action is not
well understood, PFOA’s action is suggested to be part PPAR-alphadependent and part PPAR-alpha-independent. PPAR-alpha independent is
thought to be because the branched isomers of PFOA increased liver weight
but was less effective in activating PPAR-alpha (Post, et al. 2012). Studies
suggest that PFOA increases body weight of mice even at low doses of
0.01mg/kg-0.30mg/kg (Wan et al., 2012; Yan et al., 2014). Also, in PPARalpha-null mice, PFOA is also hepatotoxic, contributing to the PPAR-alphaindependent mechanism of PFOA (Post, et al. 2012).
The EPA is investigating PFOA for possible toxic effects. Humans have
trace amounts of PFOA in serum and tissues (EPA, 2009a). The endpoints of
PFOA in humans and experimental animals are usually parallel; however,
differ in lipid metabolism outcome (Post, et al. 2012). Literature is abundant
with effects of PFOA in the liver but lacks data in adipose tissue.

This

preliminary study is one of the first to explore the mechanism of PFOA in
adipose tissue that may be attributable to its toxic effects.
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Figure 1. Overall body and organ weights after PFOA treatment. (A) Average
body weight measurements after PFOA administration.

(B) Average liver

weight measurements after PFOA administration. *, p<0.05, PFOA treatment
groups are both statistically higher than the vehicle liver weights. (C) Average
white adipose tissue weight after PFOA administration. (D) Average kidney
weight measurement after PFOA administration.

*, p<0.05, 1mg/kg PFOA

administration statistically increased average kidney weights compared to
vehicle kidney weights.

Figure 2. Fatty acid oxidation and lipid synthesis gene expression in WAT
after PFOA administration. There was no alteration in fatty acid oxidation
genes (Cyp4a14 and Ppar-a).

PFOA administration significantly increased

Srebp1c mRNA expression, but did not affect the expression of downstream
genes (e.g. Acc-1, Lpl, and Scd-1). Ppar-γ mRNA expression was similar
between groups with no statistical differences.

*, p<0.05, both PFOA

treatment groups significantly increased srebp1c gene expression compared
to vehicle.

Figure 3.

Oxidative stress target gene expression in WAT after PFOA

administration.

PFOA administration (1 mg/kg) increased nrf2 mRNA

expression in WAT. Downstream Nrf2-target genes (e.g. Nqo1, Gclc, Keap1,
Gsta-1, and AhR) did not show statistical differences between groups.
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*,p<0.05, nrf2 gene expression was statistically higher in 1mg/kg PFOA
treatment

group

compared
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to

vehicle.
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APPENDICES

Introduction
Oleanolic Acid Decreased Hepatic Cholesterol Synthesis. This appendix
material reflects a study that I helped conduct during my graduate studies. We
were not able to find a mechanism to describe the observed phenotype and
the project was a minor focus of my thesis work. I performed tissue analysis,
gene expression, and the western studies. The overall conclusion of this
study was that Oleanolic acid decreased hepatic cholesterol synthesis, but the
mechanism by which it does so was not uncovered. The appendix material
provides key data for the study.
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Introduction
Oleanolic acid (OA) is a pentacyclic triterpenic acid found in many
fruits in vegetables as secondary plant products and exists as the free acid
form eliciting many beneficial nutriceutical properties protecting against
hepatotoxicants (Prades, 2011; de Melo, 2010; Reisman, 2010). OA has been
used in Chinese medicine for the treatment of liver disorders protecting
against oxidative and electrophilic stress and activates the nuclear factor
erythroid 2-related factor 2 (Nrf2)/ kelch-like ECH-associated protein-1
(Keap1) pathway inducing expression of cytoprotectant genes (Resiman,
2010). OA is bioactively present in olive leaves, mistletoe sprouts, grape,
clove, and pomegranate flowers (de Melo, 2010).

Pharmacological and

biochemical advantages include anti-inflammatory (most attributable to the
suppression of the inducible nitric oxide synthethase gene), anti-hypertensive
(OA

attenuated

endothelial

dysfunction),

anti-diabetic,

anti-viral,

anti-

hyperlipidemic (inhibition of the ACAT gene which controls enzymes that
regulate plasma fatty acid metabolism) and hypoglycemic effects which could
be attributable to the antioxidant effect (de Melo, 2010). Pentacyclic
triterpenes also show significant suppression of tumor genesis and inhibit
tumor formation (Prades, 2011). OA has exhibited agonistic activity of TGR5,
a G-protein coupled receptor involved in energy metabolism and is a potential
drug target candidate due to its suppression of insulin resistance and antiobesity effects (Prades, 2011).
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OA administration significantly increased expression of nrf2 and its
target genes in wild-type mice including nqo-1, gclc, and ho-1, however, not in
nrf2-null mice (Reisman, 2010).

OA pretreatment reduces acetaminophen

hepatotoxicity in nrf2-null mice and more significantly in wild-type mice
(Reisman, 2010).
Butylated hydroxyanisole (BHA; 3-tert-butyl 4-hydroxyanisole) is a
synthetic phenolic compound that has been suggested to be a strong inducer
of Nrf2 and two of its downstream targets; Nqo-1 and HO-1 in rat hepatocytes
(Keum et al., 2006). BHA has been shown to induce glutathione-S-transferase
(GST) and Nqo-1 activities indicating a cytoprotective mechanism possibly
through

Nrf2

(Hayes
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et

al.,

2000).

Nuclear factor erythroid 2-related factor 2 (Nrf2) is a basic leucine-zipper
transcription factor that serves as a cellular detoxicant by endogenously
positively regulating over two hundred cytoprotective genes that defend
against stressors, such as toxic chemicals and radiation (Niture, 2011;
Sykiotis, 2011; Klaassen, 2010; Reisman, 2010; Wang, 2010; Young-Sam,
2006).

The genes include phase II drug metabolizing enzymes and

antioxidant proteins (Young-Sam, 2006). Kelch-like ECH-associated protein 1
(Keap1) acts as a tether, sequestering nrf2 in the cytoplasm, at low oxidative
and electrophilic stress level conditions (Reisman, 2010; Giudice, 2010;
Young-Sam, 2006). In the cytoplasm under low oxidative and electrophilic
stress, keap1 is an adapter of Cullin (cul) 3-based E3 ligase which promotes
nrf2 degradation (Reisman, 2010). Cul3 acts as a scaffold protein regulating
transcription factor turnover and consequently facilitates ubiquitination for
protein degradation (Resiman, 2010). Upon oxidative stress, nrf2 translocates
into the nucleus, heterodimerizes with a musculo-aponeurotic fibrosarcoma
(Maf) protein binding with antioxidant-response elements (AREs)/ electrophile
response elements (EpREs) upstream at the promoter of cytoprotectant genes
eliciting cellular defense mechanisms restoring homeostasis between oxidants
and anti-oxidants (Niture, 2011; Resiman, 2010; Wang, 2010; Giudice, 2010;
Young-Sam, 2006). Keap1 travels into the nucleus binding to NRF2
dissociating it from ARE and the complex is exported to the cytoplasm via the
nuclear export sequence of keap1 (Giudice, 2010).

Natural and synthetic

chemopreventive agents induce antioxidative and carcinogen-detoxification
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enzymes via the Nrf2/keap1 pathway (Giudice, 2010). Nrf2-null mice exhibit
an enhanced susceptibility to hepatic injury (Reisman, 2010; Klaassen, 2010).
Nrf2 controls the basal and inducible expression of mouse and human genes,
such as NQO1, HO-1, GCLs, EH-1, GSTs, SRXN-1, MRPs, BSEP, CES,
SOD1 (Klaassen, 2010; Ramos-Gomez, et al., 2001b).

Hypercholesterolemia:
Cholesterol is metabolized in two pathways; the classic and the
alternative (Tiangang, 2009). CYP7A1is the rate limiting enzyme in the classic
pathway converting cholesterol to 7-α-hydroxysterol which gets further
converted

to

cholic

acid

and

chenodeoxycholic

acid

and

further

dehydroxylated to produce secondary bile acids, deoxycholic acid and
lithocholic acid (Tiangang, 2009). CYP27A1 initiates the alternative pathway
converting cholesterol to 27-hydroxycholesterol which is further hydroxylated
by oxysterol 7α-hydroxylase via CYP7B1 (Tiangang, 2009).

Among other

reasons, cholelithiasis can arise from a decrease in CYP7A1 expression
leading to less bile acid synthesis and more cholesterol build up in the bile
creating hard substances, or, gallstones (Biddinger, 2008). Biliary cholesterol
and dietary cholesterol diverge to create luminal cholesterol (Tiangang, 2008).
Luminal cholesterol can be converted to bile acids through CYP7A1 by 7-αdehyroxylase or it can be converted to steroids by CYP11A1 (Tiangang,
2008). Before the cholesterol can be engulfed into the eneterocytes, it needs
to unite with bile acids to form micellar cholesterol (Duan, 2007). The bile
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micelle is engulfed into the enterocyte through the apical membrane NPC1L1
(Neimann-Pick C1-like protein 1) transporter (Duan, 2007).

Most of the free

cholesterol is subsequently esterified through ACAT (acetyl-Coenzyme A
acetyltransferase) while some is taken back to the liver by the MTP/CM
(microsomal triglyceride transfer protein/chylomicron) pathway. The minority
of

cholesterol

is

excreted

through

the

apical

sterol

export

pump,

ABCG5/ABCG8 (ATP-binding cassette transporters) heterodimer, from the
enterocyte into the intestinal lumen and from the hepatocytes into the bile flow
(Refer to Figure 2) (Rudkowska, 2008).

The ABC superfamily of active

transporters includes the protein G5 (ABCG5) and protein G8 (ABCG8) which
are cholesterol half transporters and come together to form a heterodimer that
functions in the transfer of sterols (Rudkowska, 2008) from enterocytes into
the intestinal lumen and from hepatocytes into bile for biliary secretion (Ikeda,
2009; Santosa, 2007; Duan, 2006). Expression of this heterodimer promotes
the efflux of cholesterol into the lumen thereby reducing cholesterol absorption
and consequently resulting in hepatic cholesterol synthesis (Santosa, 2007).
Phytosterols are also taken up by the NCP1L1 transporter into the enterocyte,
however, are not esterified and are either transported back into the lumen by
ABCG5/ABCG8 or go through the ABC1A1 to HDLs and into the periphery
(Duan, 2006). Polymorphisms in the genes that encode these transporters
have the potential to lead to sitosterolemia, hypercholesterolemia (Santosa,
2007) and gallstone formation (Rudkowska, 2008) by altering their efficacy
(Santosa, 2007).
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OA significantly decreased total cholesterol when given a HFD and OA
compared to the HFD alone (de Melo, 2010).

Study Hypothesis
The purpose of this study was to demonstrate that an nrf2 activator, oleanolic
acid, decreased hepatic cholesterol synthesis.
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Methods
Animals and Treatments: Adult C57BL/6 mice were purchased from Jackson
Laboratories (Bar Harbor, ME). Mice were housed in a temperature-, light-,
and humidity-controlled environment in cages with corn-cob bedding.

The

C57BL/6 mice were pair-wise fed i) standard diet (LM-485 Mouse/rat
sterilizable diet, Harlan Laboratories, Madison, WI) , ii) lithogenic diet (LD,
15% fat, 1.25% CH, 0.5% sodium cholate, TD03451, Harlan Laboratories,
Madison, WI), iii) standard diet with butylated hydroxyl anisole (BHA, 0.1%
w/w) or oleanolic acid (0.1% w/w), iv) LD with butylated hydroxyl anisole (0.1%
w/w) or oleanolic acid (OA, 0.1% w/w) for 6 weeks, BHA and oleanolic acid
treatments starting first. At six weeks, livers and blood were collected.

Lipid Extraction From Liver Tissue: Cholesterol and triglycerides were
extracted from liver. First, 150-200 mg of liver tissue was homogenized in a
15 mL polypropylene tube containing 3 mL of chilled PBS. 200 µL of the
homogenate was transferred into a second 15 mL polypropylene tube
preloaded with 3.75 mL of CHCl3 – MeOH (2:1). The tubes were vigorously
mixed for 20 seconds, 0.5 mL of distilled water was added, and then mixed
again for 15 seconds. The tubes were centrifuged for 5 minutes at room
temperature and spun at 3000 rpm. The chloroform layer was transferred into
a 5 mL glass tube and put into the speed vac1010 set at 45 °C for 2 hours to
allow the liquid to evaporate. The lipid residue product was re-suspended in
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200

µL

of

Ethanol

containing

1%

Triton

X-100.

Cholesterol and Triglyceride Quantification: Cholesterol and Triglyceride
quantifications were performed using colorimetric assay kits from Pointe
Scientific Inc. according to the manufacturer’s protocol. The lipid content was
quantified indirectly by measuring the amount of formazan dye produced.

RNA isolation and quantitative real-time PCR. Total RNA was isolated using
TRIzol reagent (Invitrogen, Camarillo, CA) according to the manufacturer’s
instructions. 1 μg of total RNA was converted to cDNA, and mRNA levels were
quantified by quantitative real-time PCR using a Roche LightCycler 480
System (Roche Applied Science, Mannheim, Germany). SYBR green reagent
was used, and relative target gene expression was normalized to GAPDH
mRNA.

Western Blots. Sodium dodecyl sulfate polyacrylamide gel electrophoresis was
used to separate the proteins in each of the samples. The gel used was a
10% acrylamide resolving gel with a 4% acrylamide stacking gel.
Polyvinylidene fluoride membranes were washed in Tris-buffered saline with
Tween 20 (TBS/T), incubated with primary antibody specific to the protein of
interest in 2% Non-fat dry milk in TBS/T at 4°C overnight. The membrane was
washed again and then incubated with a secondary antibody specific to the
primary antibody used in 2% Non-fat dry milk in TBS/T for 1 hour.
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The

membrane was then incubated with ECL+ chemiluminescent substrate (GE
Healthcare Life Sciences, Pittsburgh, PA) and visualized using light sensitive
film.

The concentration of the proteins in each sample can be seen by

quantification of the bands seen in the developed light sensitive film and
normalized to β-actin.
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Results
The effect of oleanolic acid on serum and hepatic cholesterol levels in
mice. OA has been used in Chinese medicine for the treatment of liver
disorders protecting against oxidative and electrophilic stress and activates the
nuclear factor erythroid 2-related factor 2/ kelch-like ECH-associated protein 1
pathway inducing expression of cytoprotectant genes (Resiman, 2010).

The effect of oleanolic acid feeding on lithogenic diet-induced
cholesterol uptake, synthesis, and transport gene expression in liver.
Abcg5/abcg8 is a heterodimer responsible for cholesterol excretion from liver
to the bile.

Abca1 resides in the basolateral membrane transporting

cholesterol back into the blood to lipid-poor lipoproteins. Ldlr is responsible for
the uptake of cholesterol into the liver and hmg-coar is the rate limiting
enzyme in which cholesterol is synthesized.

The lithogenic diet alone

increased abcg5/abcg8 mRNA expression 4-fold. OA administration with the
lithogenic diet increased abcg5/abcg8 mRNA expression 3.5-fold.

Abca1

mRNA expression was increased 2.5-fold on the lithogenic diet alone and 2fold with OA on the lithogenic diet.

Ldlr mRNA expression was slightly

decreased on the lithogenic diet and more decreased with OA administration
on the lithogenic diet. Hmg-coaR was decreased 3-fold and 5-fold on the
lithogenic diet and lithogenic diet with OA respectively.
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The effect of oleanolic acid feeding on lithogenic diet-induced bile acid
uptake, synthesis, and transport gene expression in liver. Cyp7a1 is the
rate-limiting enzyme in which cholesterol is converted to bile acids. Bsep is
the bile salt export pumped from the liver into the bile. The lithogenic diet
alone increased bsep mRNA expression slightly, and even more in the
lithogenic diet with OA administration.

The effect of oleanolic acid feeding on Nrf2 and Nrf2-target gene
expression in liver. OA administration significantly increased expression of
nrf2 and its target genes in wild-type mice including nqo-1, gclc, and ho-1,
however, not in nrf2-null mice (Reisman, 2010).

102

Conclusion
OA and BHA are two compounds that are considered to be Nrf2-activators. In
In this study, adult male C57BL/6 mice were pair-wise fed ad libitum i)
standard diet (CONT), ii) lithogenic diet (LD, 15% fat, 1.25% CH, 0.5% sodium
cholate), iii) standard diet with oleanolic acid (0.1% w/w), iv) LD with oleanolic
acid (OA, 0.1% w/w) for six weeks.

BHA reduced body weight, however

increased the liver weights of mice. BHA treatment doubled serum cholesterol
levels in mice fed the lithogenic diet compared to mice that received lithogenic
diet alone. Mice treated with OA in their diets have similar serum cholesterol
levels to untreated mice. However, the overall finding of this study was that
Oleanolic acid decreased hepatic cholesterol content.
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Figures. Adult male C57BL/6 mice were pair-wise fed ad libitum i) standard
diet (CONT), ii) lithogenic diet (LD, 15% fat, 1.25% CH, 0.5% sodium cholate),
iii) standard diet with oleanolic acid (0.1% w/w), iv) LD with oleanolic acid (OA,
0.1% w/w) for six weeks. Mice were sacrificed and livers, gallbladders and
serum were collected.

The serum cholesterol levels were determined by

colorimetric assay. The cholesterol contents were quantified by measuring the
amount of formazan dye produced. Asterisks (*) represent a statistical
difference (p < 0.05) between standard diet and lithogenic diet groups. Double
Daggers (‡) represent a statistical difference (p < 0.05) between OA and the
controls. The lithogenic increased serum cholesterol levels in controls (CONT)
fed diet only by 40%. BHA treatment doubled serum cholesterol levels in mice
fed the lithogenic diet compared to mice that received lithogenic diet alone.
Mice treated with OA in their diets have similar serum cholesterol levels to
untreated mice.
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FIGURE 2
BHA and OA elevate serum cholesterol levels in C57Bl/6 mice
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